1. Home
  2. RNTX vs JVA Comparison

RNTX vs JVA Comparison

Compare RNTX & JVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • JVA
  • Stock Information
  • Founded
  • RNTX 2001
  • JVA 1971
  • Country
  • RNTX United States
  • JVA United States
  • Employees
  • RNTX N/A
  • JVA N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • JVA Packaged Foods
  • Sector
  • RNTX Health Care
  • JVA Consumer Staples
  • Exchange
  • RNTX Nasdaq
  • JVA Nasdaq
  • Market Cap
  • RNTX 26.5M
  • JVA 23.8M
  • IPO Year
  • RNTX N/A
  • JVA 2005
  • Fundamental
  • Price
  • RNTX $1.34
  • JVA $4.17
  • Analyst Decision
  • RNTX Hold
  • JVA
  • Analyst Count
  • RNTX 1
  • JVA 0
  • Target Price
  • RNTX N/A
  • JVA N/A
  • AVG Volume (30 Days)
  • RNTX 65.2K
  • JVA 39.4K
  • Earning Date
  • RNTX 08-14-2025
  • JVA 09-12-2025
  • Dividend Yield
  • RNTX N/A
  • JVA N/A
  • EPS Growth
  • RNTX N/A
  • JVA 856.08
  • EPS
  • RNTX N/A
  • JVA 0.65
  • Revenue
  • RNTX N/A
  • JVA $84,651,329.00
  • Revenue This Year
  • RNTX N/A
  • JVA N/A
  • Revenue Next Year
  • RNTX N/A
  • JVA N/A
  • P/E Ratio
  • RNTX N/A
  • JVA $6.47
  • Revenue Growth
  • RNTX N/A
  • JVA 15.86
  • 52 Week Low
  • RNTX $1.04
  • JVA $1.86
  • 52 Week High
  • RNTX $4.40
  • JVA $9.93
  • Technical
  • Relative Strength Index (RSI)
  • RNTX 49.84
  • JVA 43.91
  • Support Level
  • RNTX $1.06
  • JVA $4.05
  • Resistance Level
  • RNTX $1.21
  • JVA $4.21
  • Average True Range (ATR)
  • RNTX 0.10
  • JVA 0.12
  • MACD
  • RNTX 0.02
  • JVA -0.01
  • Stochastic Oscillator
  • RNTX 66.67
  • JVA 15.71

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.

Share on Social Networks: